VirginiaRBartonMD

Clinical Trials

• Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) Start of enrollment: 2017 Nov 30

  Completed

  Phase 2, Phase 3

• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Start of enrollment: 2015 Oct 15

  Active, not recruiting

  Phase 3

• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Start of enrollment: 2018 Sep 24

  Active, not recruiting

  Phase 2, Phase 3

• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Feb 20

  Completed

  Phase 3

• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27

  Terminated

  Phase 3

• Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Start of enrollment: 2019 Dec 30

  Active, not recruiting

  Phase 3

• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2019 Jun 30

  Completed

  Phase 3

• A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis Start of enrollment: 2019 May 01

  Terminated

  Phase 2

• PRISM Study-Pruritus Relief Through Itch Scratch Modulation Start of enrollment: 2018 Aug 07

  Completed

  Phase 2, Phase 3

• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17

  Completed

  Phase 3

• A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Start of enrollment: 2018 Dec 21

  Recruiting

• Observational Evaluation of Atopic Dermatitis in Pediatric Patients Start of enrollment: 2019 Aug 15

  Recruiting

• Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) Start of enrollment: 2019 Apr 05

  Active, not recruiting

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2020 Mar 02

  Completed

  Phase 3

• Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis Start of enrollment: 2018 Dec 19

  Terminated

  Phase 3

• Join now to see all